ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/16/20

Big cash flows from a handful of successful new cancer drugs recently emboldened AstraZeneca (NASDAQ: AZN) to make a huge bet on Alexion Pharmaceuticals (NASDAQ: ALXN) and its successful drugs for rare diseases. AstraZeneca offered $39 billion for Alexion in a combi...

Palm Beach, FL – December 15, 2020 – While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient’s body? The simplest way is usuall...

Looking To Add Biotech Stocks To Your Watchlist? 3 Making Moves This Week It has clearly been the year of biotech stocks in the stock market. Investors and biotech companies alike will likely agree. Most of the top biotech stocks have seen massive rallies throughout this yea...

Moderna's COVID-19 vaccine has shown efficacy on par with Pfizer's. However, PFE will be first to market. MRNA's vaccine could generate $11 billion in 2021 revenue. The company trades at 5.6x 2021 projected COVID-19 revenue. Moderna's revenue is expected to decline over time. Its ...

The drug portfolio of Alexion Pharmaceuticals (ALXN) is led by C5-inhibitors: Ultomiris (ALXN1210/ravulizumab-cwvz) and Soliris (eculizumab). In the wake of its proposed merger with AstraZeneca (AZN), even clinical-stage biopharmaceutical companies focused on complement-mediated therapies hav...

Investors have watched the Nasdaq Composite (NASDAQINDEX: ^IXIC) closely, especially given how much it has outperformed the broader market. Optimism about the stock market's prospects for 2021 has given the tech-heavy benchmark a boost lately, and the Nasdaq's gain of more than 1% a...

Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...

Commenting on the proposed merger between Alexion (ALXN) and AstraZeneca (AZN), Piper Sandler highlights the ‘durability’ of large biotech businesses, ‘with Astra pointing to double-digit EPS accretion in years 1-3’ from the deal.“If the market doe...

Shares of the rare-disease specialist Alexion Pharmaceuticals (NASDAQ: ALXN) are up by a healthy 30.6% as of 10:03 a.m. EST Monday morning. The biotech's shares are roaring higher this morning in response to a $39 billion buyout agreement with British and Swedish pharma giant Astr...

The consolidation of biopharma customers is 'a risk to CROs’ as it can lead to downsizing of R&D budgets and outsourcing, Bank of America says in a note evaluating the impact on IQVIA Holdings (IQV) from the proposed merger between Alexion (ALXN) and AstraZeneca (AZN).Identifying I...